1
|
Dragowska WH, Weppler SA, Chu WW, Chow NS, Rawji JS, Prasad AS, Gelmon KA, Gorski SM, Bally MB. Abstract 271: Influence of autophagy modulation on synergistic interactions of lapatinib and mTOR targeted agents in HER2-amplified lapatinib resistant breast cancer models in vitro and in vivo. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Resistance against HER2 targeted agents ultimately limits the therapeutic success in patients with HER2-positive breast cancer. It was shown that PIK3CA mutations contribute to lapatinib resistance and achieving control of a downstream PI3K/mTOR signaling is necessary for optimal effectiveness of HER2 blockade. We and others have shown that catalytic mTORC1/2 inhibitors reverse lapatinib resistance and inhibit growth of HER2-overexpressing breast cancer models in vitro and in vivo. However, activity of these targeted agents is hindered by the compensatory and adaptive mechanisms that arise to assure cell survival. One of the pro-survival responses is cytoprotective autophagy induced by lapatinib and mTORC1/2 inhibitors. Thus, we examined whether impairing autophagy could augment activity of lapatinib/mTORC1/2 inhibitors combinations in lapatinib-resistant breast cancer models. Methods: The combination of lapatinib with catalytic mTORC1/2 inhibitors KU-0063794 (KU) or AZD2014 (AZD) was evaluated in vitro and in vivo in lapatinib resistant PIK3CA mutated HER2-overexpressing/amplified MDA-MB-361, JIMT-1 and MDA-MB-453 breast cancer models in the presence of siRNA-based (Atg7, Beclin-1) and pharmacological (hydroxychloroquine (HCQ)) inhibitors of autophagy. Results: In vitro lapatinib/mTORC1/2 combinations elevated autophagy to a greater extent that either compound alone. Genetic or pharmacological inhibition of treatment-induced autophagy further decreased cell viability, suggesting that autophagy was playing a cytoprotective role in this context. In vivo, lapatinib and AZD combinations achieved effective tumor growth inhibition of 98%, 111% and 152% in MDA-MB-361, JIMT-1 and MDA-MB-453 models respectively, however addition of HCQ did not significantly enhance this therapeutic response (p>0.05). Conclusion: Negligible effects of HCQ in vivo in tumors treated with lapatinib/AZD combinations may be attributed to ineffective inhibition of autophagy-mediated survival signals that, if significantly blocked, could increase efficacy of the treatment. Utilizing carrier nanotechnology to optimize delivery of HCQ to the tumor site and molecular analysis of HCQ-engendered off target effects on survival and proliferation pathways in tumor tissue are being pursued.
Citation Format: Wieslawa H. Dragowska, Sherry A. Weppler, William Wei Chu, Norman S. Chow, Jenna S. Rawji, Ashleen S. Prasad, Karen A. Gelmon, Sharon M. Gorski, Marcel B. Bally. Influence of autophagy modulation on synergistic interactions of lapatinib and mTOR targeted agents in HER2-amplified lapatinib resistant breast cancer models in vitro and in vivo. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 271.
Collapse
Affiliation(s)
- Wieslawa H. Dragowska
- 1Experimental Therapeutics Laboratory, BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Sherry A. Weppler
- 1Experimental Therapeutics Laboratory, BC Cancer Agency, Vancouver, British Columbia, Canada
| | - William Wei Chu
- 1Experimental Therapeutics Laboratory, BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Norman S. Chow
- 1Experimental Therapeutics Laboratory, BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Jenna S. Rawji
- 1Experimental Therapeutics Laboratory, BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Ashleen S. Prasad
- 1Experimental Therapeutics Laboratory, BC Cancer Agency, Vancouver, British Columbia, Canada
| | - Karen A. Gelmon
- 2Medical Oncology, BC Cancer Agency; Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Sharon M. Gorski
- 3Michael Smith Genome Sciences Centre, BC Cancer Agency; Department of Molecular Biology and Biochemistry, Simon Fraser University, Vancouver and Burnaby, British Columbia, Canada
| | - Marcel B. Bally
- 4Experimental Therapeutics Laboratory, BC Cancer Agency, Faculty of Pharmaceutical Sciences, Department of Pathology and Laboratory Medicine, University of British Columbia; Centre for Drug Research and Development, Vancouver, British Columbia, Canada
| |
Collapse
|
2
|
Dragowska WH, Weppler SA, Wang JC, Wong LY, Kapanen AI, Rawji JS, Warburton C, Qadir MA, Donohue E, Roberge M, Gorski SM, Gelmon KA, Bally MB. Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer. PLoS One 2013; 8:e76503. [PMID: 24146879 PMCID: PMC3795739 DOI: 10.1371/journal.pone.0076503] [Citation(s) in RCA: 81] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2013] [Accepted: 08/27/2013] [Indexed: 12/14/2022] Open
Abstract
Gefitinib (Iressa(®), ZD1839) is a small molecule inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. We report on an early cellular response to gefitinib that involves induction of functional autophagic flux in phenotypically diverse breast cancer cells that were sensitive (BT474 and SKBR3) or insensitive (MCF7-GFPLC3 and JIMT-1) to gefitinib. Our data show that elevation of autophagy in gefitinib-treated breast cancer cells correlated with downregulation of AKT and ERK1/2 signaling early in the course of treatment. Inhibition of autophagosome formation by BECLIN-1 or ATG7 siRNA in combination with gefitinib reduced the abundance of autophagic organelles and sensitized SKBR3 but not MCF7-GFPLC3 cells to cell death. However, inhibition of the late stage of gefitinib-induced autophagy with hydroxychloroquine (HCQ) or bafilomycin A1 significantly increased (p<0.05) cell death in gefitinib-sensitive SKBR3 and BT474 cells, as well as in gefitinib-insensitive JIMT-1 and MCF7-GFPLC3 cells, relative to the effects observed with the respective single agents. Treatment with the combination of gefitinib and HCQ was more effective (p<0.05) in delaying tumor growth than either monotherapy (p>0.05), when compared to vehicle-treated controls. Our results also show that elevated autophagosome content following short-term treatment with gefitinib is a reversible response that ceases upon removal of the drug. In aggregate, these data demonstrate that elevated autophagic flux is an early response to gefitinib and that targeting EGFR and autophagy should be considered when developing new therapeutic strategies for EGFR expressing breast cancers.
Collapse
Affiliation(s)
- Wieslawa H. Dragowska
- Department of Experimental Therapeutics, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
| | - Sherry A. Weppler
- Department of Experimental Therapeutics, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
| | - Jun Chih Wang
- Department of Experimental Therapeutics, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
| | - Ling Yan Wong
- Department of Experimental Therapeutics, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
| | - Anita I. Kapanen
- Department of Experimental Therapeutics, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
| | - Jenna S. Rawji
- Department of Experimental Therapeutics, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
| | - Corinna Warburton
- Department of Experimental Therapeutics, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
| | - Mohammed A. Qadir
- Department of Experimental Therapeutics, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
| | - Elizabeth Donohue
- Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada
| | - Michel Roberge
- Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada
- Center for Drug Research and Development, Vancouver, British Columbia, Canada
| | - Sharon M. Gorski
- Michael Smith Genome Sciences Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
- Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, British Columbia, Canada
| | - Karen A. Gelmon
- Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
- Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Marcel B. Bally
- Department of Experimental Therapeutics, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
- Center for Drug Research and Development, Vancouver, British Columbia, Canada
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
- Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| |
Collapse
|
3
|
Weppler SA, Dragowska WH, Kierkels GJ, Rawji J, Gorski SM, Bally MB. Abstract 4469: Combating lapatinib resistance of HER2 positive breast cancer cells by combined inhibition of mTOR and autophagy. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-4469] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Lapatinib, a dual epidermal growth factor receptor 1 (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitor, has emerged as a second line therapy for breast cancer patients who relapse following trastuzumab and is being tested in clinical trials as a single agent or in combination settings. However, like trastuzumab, development of resistance to lapatinib presents a problem in the clinic. A number of mechanisms have been proposed to explain both intrinsic and acquired resistance to HER2 targeted therapies, one of which involves upregulation of signaling through the PI3K/Akt/mTOR pathway. Thus, we tested if resistance to lapatinib can be overcome by drug combinations that achieve control over both HER2 and mTOR signaling. Our results showed that lapatinib in combination with KU-0063794 (KU), a catalytic mTOR kinase inhibitor that blocks mTORC1 and mTORC2 signaling, had a synergistic effect on cell growth inhibition in both lapatinib sensitive and resistant cell lines. The combination of these two inhibitors achieved a more effective blockade of signaling downstream of mTORC1 than either inhibitor alone as measured by decreased phosphorylation of 4E-BP1 and S6. Due to links between mTOR and autophagy, we also examined how these inhibitors may be influencing the autophagy process. To measure autophagic flux we used a combination of immunoblotting against LC3-II, a marker of autophagic vesicles, and p62, an adaptor protein that is selectively degraded upon autophagosome-lysosome fusion. Both lapatinib and KU induced expression of LC3-II and reduced p62 levels, together suggesting that these inhibitors increase autophagic flux. Using monodansylcadaverine (MDC) to label autophagic vesicles, we found that the combination of lapatinib and KU increased the total MDC-positive vesicle area per cell to a greater extent than an equimolar concentration of either compound alone. Since autophagy is considered a survival mechanism, we tested whether impairing this process with hydroxychloroquine (HCQ), a compound that blocks autophagic flux, may augment activity of the lapatinib and KU combination. Cell viability as assessed by an alamar blue assay showed that inhibition of cell growth by lapatinib and KU was further enhanced by addition of HCQ in JIMT-1 and MDA-MB-361 cells. In addition, live cell imaging of caspase-3/7 activation in MDA-MB-361 showed that HCQ increased the number of apoptotic cells induced by the lapatinib and KU combination from 32% to 78% at the highest dose tested. The efficacy of this triple combination is currently being tested in xenograft models. In conclusion, lapatinib resistance of two HER2 overexpressing cell lines can be effectively reversed by treating cells with a combination of lapatinib, a catalytic mTOR inhibitor, and an autophagy inhibitor. This may be a feasible treatment strategy for relapsed or metastatic HER2 positive breast cancer.
Citation Format: Sherry A. Weppler, Wieslawa H. Dragowska, Guido J. Kierkels, Jenna Rawji, Sharon M. Gorski, Marcel B. Bally. Combating lapatinib resistance of HER2 positive breast cancer cells by combined inhibition of mTOR and autophagy. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4469. doi:10.1158/1538-7445.AM2013-4469
Collapse
Affiliation(s)
- Sherry A. Weppler
- 1British Columbia Cancer Agency, Vancouver, British Columbia, Canada
| | | | - Guido J. Kierkels
- 1British Columbia Cancer Agency, Vancouver, British Columbia, Canada
| | - Jenna Rawji
- 1British Columbia Cancer Agency, Vancouver, British Columbia, Canada
| | - Sharon M. Gorski
- 2Michael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada
| | - Marcel B. Bally
- 1British Columbia Cancer Agency, Vancouver, British Columbia, Canada
| |
Collapse
|
4
|
Verreault M, Weppler SA, Stegeman A, Warburton C, Strutt D, Masin D, Bally MB. Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model. PLoS One 2013; 8:e59597. [PMID: 23555046 PMCID: PMC3598699 DOI: 10.1371/journal.pone.0059597] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2011] [Accepted: 02/19/2013] [Indexed: 12/19/2022] Open
Abstract
The PI3K/AKT/mTOR pathway is commonly over activated in glioblastoma (GBM), and Rictor was shown to be an important regulator downstream of this pathway. EGFR overexpression is also frequently found in GBM tumors, and both EGFR and Rictor are associated with increased proliferation, invasion, metastasis and poor prognosis. This research evaluated in vitro and in vivo whether the combined silencing of EGFR and Rictor would result in therapeutic benefits. The therapeutic potential of targeting these proteins in combination with conventional agents with proven activity in GBM patients was also assessed. In vitro validation studies were carried out using siRNA-based gene silencing methods in a panel of three commercially available human GBM cell lines, including two PTEN mutant lines (U251MG and U118MG) and one PTEN-wild type line (LN229). The impact of EGFR and/or Rictor silencing on cell migration and sensitivity to chemotherapeutic drugs in vitro was determined. In vivo validation of these studies was focused on EGFR and/or Rictor silencing achieved using doxycycline-inducible shRNA-expressing U251MG cells implanted orthotopically in Rag2M mice brains. Target silencing, tumor size and tumor cell proliferation were assessed by quantification of immunohistofluorescence-stained markers. siRNA-mediated silencing of EGFR and Rictor reduced U251MG cell migration and increased sensitivity of the cells to irinotecan, temozolomide and vincristine. In LN229, co-silencing of EGFR and Rictor resulted in reduced cell migration, and increased sensitivity to vincristine and temozolomide. In U118MG, silencing of Rictor alone was sufficient to increase this line’s sensitivity to vincristine and temozolomide. In vivo, while the silencing of EGFR or Rictor alone had no significant effect on U251MG tumor growth, silencing of EGFR and Rictor together resulted in a complete eradication of tumors. These data suggest that the combined silencing of EGFR and Rictor should be an effective means of treating GBM.
Collapse
Affiliation(s)
- Maite Verreault
- Experimental Neurooncology, Brain and Bone Marrow Institute Research Center, Pitie-Salpetriere Hospital, Paris, France
- * E-mail: (MV); (MBB)
| | - Sherry A. Weppler
- Experimental Therapeutics, British Columbia Cancer Agency, Vancouver, BC, Canada
| | - Amelia Stegeman
- Experimental Therapeutics, British Columbia Cancer Agency, Vancouver, BC, Canada
| | - Corinna Warburton
- Experimental Therapeutics, British Columbia Cancer Agency, Vancouver, BC, Canada
| | - Dita Strutt
- Experimental Therapeutics, British Columbia Cancer Agency, Vancouver, BC, Canada
| | - Dana Masin
- Experimental Therapeutics, British Columbia Cancer Agency, Vancouver, BC, Canada
| | - Marcel B. Bally
- Experimental Therapeutics, British Columbia Cancer Agency, Vancouver, BC, Canada
- Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver BC, Canada
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver BC, Canada
- Center for Drug Research and Development, Vancouver, BC, Canada
- * E-mail: (MV); (MBB)
| |
Collapse
|
5
|
Dragowska WH, Weppler SA, Qadir MA, Wong LY, Franssen Y, Baker JHE, Kapanen AI, Kierkels GJJ, Masin D, Minchinton AI, Gelmon KA, Bally MB. The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity. BMC Cancer 2011; 11:420. [PMID: 21961653 PMCID: PMC3207940 DOI: 10.1186/1471-2407-11-420] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2011] [Accepted: 10/01/2011] [Indexed: 11/13/2022] Open
Abstract
Background HER2-positive breast cancers exhibit high rates of innate and acquired resistance to trastuzumab (TZ), a HER2-directed antibody used as a first line treatment for this disease. TZ resistance may in part be mediated by frequent co-expression of EGFR and by sustained activation of the mammalian target of rapamycin (mTOR) pathway. Here, we assessed feasibility of combining the EGFR inhibitor gefitinib and the mTOR inhibitor everolimus (RAD001) for treating HER2 overexpressing breast cancers with different sensitivity to TZ. Methods The gefitinib and RAD001 combination was broadly evaluated in TZ sensitive (SKBR3 and MCF7-HER2) and TZ resistant (JIMT-1) breast cancer models. The effects on cell growth were measured in cell based assays using the fixed molar ratio design and the median effect principle. In vivo studies were performed in Rag2M mice bearing established tumors. Analysis of cell cycle, changes in targeted signaling pathways and tumor characteristics were conducted to assess gefitinib and RAD001 interactions. Results The gefitinib and RAD001 combination inhibited cell growth in vitro in a synergistic fashion as defined by the Chou and Talalay median effect principle and increased tumor xenograft growth delay. The improvement in therapeutic efficacy by the combination was associated in vitro with cell line dependent increases in cytotoxicity and cytostasis while treatment in vivo promoted cytostasis. The most striking and consistent therapeutic effect of the combination was increased inhibition of the mTOR pathway (in vitro and in vivo) and EGFR signaling in vivo relative to the single drugs. Conclusions The gefitinib and RAD001 combination provides effective control over growth of HER2 overexpressing cells and tumors irrespective of the TZ sensitivity status.
Collapse
Affiliation(s)
- Wieslawa H Dragowska
- Experimental Therapeutics, British Columbia Cancer Agency, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Dubois L, Magagnin MG, Cleven AHG, Weppler SA, Grenacher B, Landuyt W, Lieuwes N, Lambin P, Gorr TA, Koritzinsky M, Wouters BG. Inhibition of 4E-BP1 sensitizes U87 glioblastoma xenograft tumors to irradiation by decreasing hypoxia tolerance. Int J Radiat Oncol Biol Phys 2009; 73:1219-27. [PMID: 19251093 DOI: 10.1016/j.ijrobp.2008.12.003] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2008] [Revised: 11/18/2008] [Accepted: 12/02/2008] [Indexed: 01/12/2023]
Abstract
PURPOSE Eukaryotic initiation factor 4E (eIF4E) is an essential rate-limiting factor for cap-dependent translation in eukaryotic cells. Elevated eIF4E activity is common in many human tumors and is associated with disease progression. The growth-promoting effects of eIF4E are in turn negatively regulated by 4E-BP1. However, although 4E-BP1 harbors anti-growth activity, its expression is paradoxically elevated in some tumors. The aim of this study was to investigate the functional role of 4E-BP1 in the context of solid tumors. METHODS AND MATERIALS In vitro and in vivo growth properties, hypoxia tolerance, and response to radiation were assessed for HeLa and U87 cells, after stable expression of shRNA specific for 4E-BP1. RESULTS We found that loss of 4E-BP1 expression did not significantly alter in vitro growth but did accelerate the growth of U87 tumor xenografts, consistent with the growth-promoting function of deregulated eIF4E. However, cells lacking 4E-BP1 were significantly more sensitive to hypoxia-induced cell death in vitro. Furthermore, 4E-BP1 knockdown cells produced tumors more sensitive to radiation because of a reduction in the viable fraction of radioresistant hypoxic cells. Decreased hypoxia tolerance in the 4E-BP1 knockdown tumors was evident by increased cleaved caspase-3 levels and was associated with a reduction in adenosine triphosphate (ATP). CONCLUSIONS Our results suggest that although tumors often demonstrate increases in cap-dependent translation, regulation of this activity is required to facilitate energy conservation, hypoxia tolerance, and tumor radioresistance. Furthermore, we suggest that targeting translational control may be an effective way to target hypoxic cells and radioresistance in metabolically hyperactive tumors.
Collapse
Affiliation(s)
- Ludwig Dubois
- Department of Radiation Oncology (Maastro Laboratory), GROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Aerts HJWL, Dubois L, Hackeng TM, Straathof R, Chiu RK, Lieuwes NG, Jutten B, Weppler SA, Lammering G, Wouters BG, Lambin P. Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII. Radiother Oncol 2007; 83:326-32. [PMID: 17531336 DOI: 10.1016/j.radonc.2007.04.030] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2007] [Revised: 04/23/2007] [Accepted: 04/23/2007] [Indexed: 11/28/2022]
Abstract
BACKGROUND AND PURPOSE The epidermal growth factor receptor (EGFR) is overexpressed in a significant percentage of human malignancies and its expression is associated with tumour aggressiveness and treatment resistance. The monoclonal antibody cetuximab (IMC-C225) blocks the ligand-binding domain of EGFR with high affinity, preventing downstream signalling resulting in tumour growth inhibition. We developed and characterized a novel imaging probe using Oregon Green 488 labelled cetuximab to evaluate its usage as an imaging agent to target EGFR. MATERIALS AND METHODS Cells with varying expression levels of EGFR or a mutant form of EGFR, called EGFRvIII, were used for in vitro validation. The in vivo binding of labelled cetuximab to EGFR was also assessed ex vivo on tumour material. RESULTS The development of Oregon Green 488 labelled cetuximab was successful, demonstrating binding to both EGFR and EGFRvIII in vitro. Accumulation was also found in vivo, which was confirmed by histopathology using anti-EGFR antibodies. However, significant mismatch highlights differences between drug delivery in vivo, and cell expression levels of EGFR. CONCLUSIONS The monoclonal antibody cetuximab represents a promising probe to evaluate the biologic and pharmacokinetic effects of in vivo cetuximab binding to EGFR. It not only visualizes the presence of the wild type EGFR, but also the presence of the mutant EGFRvIII.
Collapse
Affiliation(s)
- Hugo J W L Aerts
- Department of Radiation Oncology (MAASTRO), GROW Research Institute, University of Maastricht, The Netherlands.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Weppler SA, Li Y, Dubois L, Lieuwes N, Jutten B, Lambin P, Wouters BG, Lammering G. Expression of EGFR variant vIII promotes both radiation resistance and hypoxia tolerance. Radiother Oncol 2007; 83:333-9. [PMID: 17512071 DOI: 10.1016/j.radonc.2007.04.025] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2007] [Revised: 04/27/2007] [Accepted: 04/27/2007] [Indexed: 11/27/2022]
Abstract
BACKGROUND AND PURPOSE EGFRvIII has been described to function as an oncoprotein with constitutive activation promoting neoplastic transformation and tumorigenicity. The present study was undertaken to test whether EGFRvIII also contributes to hypoxia tolerance. MATERIAL AND METHODS The human glioma cell line U373 was genetically modified to stably express EGFRvIII. Western blotting and immunohistochemistry verified the expression of EGFRvIII. Tumour xenografts were produced by injecting U373 control and EGFRvIII positive cells subcutaneously into the lateral flank of recipient mice. Colony formation assays were performed after ionizing radiation at 4Gy and after exposure to anoxia for 1-4 days. RESULTS EGFRvIII accelerated tumour growth leading to a 3.5-fold increase in tumour size compared to control tumours at 40 days after cell injection. EGFRvIII promoted clonogenic survival by almost 2-fold and 4-fold after 4Gy and 4 days of anoxia, respectively. EGFRvIII was also associated with a substantially bigger colony size after anoxic treatment. CONCLUSIONS EGFRvIII expression stimulates the growth of tumour xenografts and strongly promotes survival after irradiation and under hypoxic stress.
Collapse
Affiliation(s)
- Sherry A Weppler
- Maastricht Radiation Oncology (MAASTRO) Lab, GROW Research Institute, University of Maastricht, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Weppler SA, Krause M, Zyromska A, Lambin P, Baumann M, Wouters BG. Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: Possible role for thrombosis. Radiother Oncol 2007; 82:96-104. [PMID: 17161482 DOI: 10.1016/j.radonc.2006.11.004] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2006] [Revised: 10/30/2006] [Accepted: 11/03/2006] [Indexed: 01/14/2023]
Abstract
BACKGROUND AND PURPOSE Rapamycin, a highly specific mTOR inhibitor, has shown anti-proliferative and anti-angiogenic properties, as well as an enhancement in tumour growth delay when used in combination with radiation in mouse xenograft models. Our goal was to determine if rapamycin can also have a positive effect on the local tumour control achieved by radiotherapy. MATERIALS AND METHODS Nude mice bearing U87 glioblastoma xenografts were treated with concomitant rapamycin and radiotherapy over a 5 day fractionation schedule. Animals received graded total doses ranging from 24 to 100 Gy. Experimental endpoints were tumour growth delay and local tumour control. In addition, histological evaluation of tumour sections was performed to examine changes occurring within the tumour microenvironment as a result of treatment. Analysis of proliferation, mTOR signalling, hypoxia, and vessel thrombosis was conducted. RESULTS As a single agent, rapamycin reduced the in vitro growth of U87 cells by 70% and caused a 4 day growth delay of tumour xenografts. In combination with radiation, no further increase in tumour growth delay was observed when compared to radiation alone. The tumour control dose 50% (TCD(50)) was 46.8 Gy (95% CI 41; 53 Gy) in tumours treated with radiation alone and was slightly but not significantly lower at 42.8 Gy (95% CI 36; 49 Gy) after simultaneous treatment with rapamycin. Histological evaluation revealed evidence of elevated hypoxia following rapamycin treatment that may be due to vessel thrombosis. CONCLUSIONS The influence of rapamycin on thrombosis and tumour hypoxia may be a confounding factor limiting its effectiveness in combination with radiotherapy.
Collapse
Affiliation(s)
- Sherry A Weppler
- Maastricht Radiation Oncology (Maastro), GROW Research Institute, University Maastricht, Maastricht, The Netherlands
| | | | | | | | | | | |
Collapse
|
10
|
Koritzinsky M, Magagnin MG, van den Beucken T, Seigneuric R, Savelkouls K, Dostie J, Pyronnet S, Kaufman RJ, Weppler SA, Voncken JW, Lambin P, Koumenis C, Sonenberg N, Wouters BG. Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. EMBO J 2006; 25:1114-25. [PMID: 16467844 PMCID: PMC1409715 DOI: 10.1038/sj.emboj.7600998] [Citation(s) in RCA: 272] [Impact Index Per Article: 15.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2005] [Accepted: 01/18/2006] [Indexed: 12/13/2022] Open
Abstract
Hypoxia has recently been shown to activate the endoplasmic reticulum kinase PERK, leading to phosphorylation of eIF2alpha and inhibition of mRNA translation initiation. Using a quantitative assay, we show that this inhibition exhibits a biphasic response mediated through two distinct pathways. The first occurs rapidly, reaching a maximum at 1-2 h and is due to phosphorylation of eIF2alpha. Continued hypoxic exposure activates a second, eIF2alpha-independent pathway that maintains repression of translation. This phase is characterized by disruption of eIF4F and sequestration of eIF4E by its inhibitor 4E-BP1 and transporter 4E-T. Quantitative RT-PCR analysis of polysomal RNA indicates that the translation efficiency of individual genes varies widely during hypoxia. Furthermore, the translation efficiency of individual genes is dynamic, changing dramatically during hypoxic exposure due to the initial phosphorylation and subsequent dephosphorylation of eIF2alpha. Together, our data indicate that acute and prolonged hypoxia regulates mRNA translation through distinct mechanisms, each with important contributions to hypoxic gene expression.
Collapse
Affiliation(s)
- Marianne Koritzinsky
- Department of Radiation Oncology (Maastro), GROW Research Institute, University of Maastricht, The Netherlands
| | - Michaël G Magagnin
- Department of Radiation Oncology (Maastro), GROW Research Institute, University of Maastricht, The Netherlands
| | - Twan van den Beucken
- Department of Radiation Oncology (Maastro), GROW Research Institute, University of Maastricht, The Netherlands
| | - Renaud Seigneuric
- Department of Radiation Oncology (Maastro), GROW Research Institute, University of Maastricht, The Netherlands
| | - Kim Savelkouls
- Department of Radiation Oncology (Maastro), GROW Research Institute, University of Maastricht, The Netherlands
| | - Josée Dostie
- Department of Biochemistry, McGill Cancer Centre, McGill University, Canada
| | - Stéphane Pyronnet
- Department of Biochemistry, McGill Cancer Centre, McGill University, Canada
| | - Randal J Kaufman
- Howard Hughes Medical Institute, University of Michigan Medical Center, USA
| | - Sherry A Weppler
- Department of Radiation Oncology (Maastro), GROW Research Institute, University of Maastricht, The Netherlands
| | - Jan Willem Voncken
- Department of Molecular Genetics, University of Maastricht, The Netherlands
| | - Philippe Lambin
- Department of Radiation Oncology (Maastro), GROW Research Institute, University of Maastricht, The Netherlands
| | - Constantinos Koumenis
- Departments of Radiation Oncology and Cancer Biology, Wake Forest University School of Medicine, USA
| | - Nahum Sonenberg
- Department of Biochemistry, McGill Cancer Centre, McGill University, Canada
| | - Bradly G Wouters
- Department of Radiation Oncology (Maastro), GROW Research Institute, University of Maastricht, The Netherlands
- Department of Radiation Oncology (Maastro), GROW Research Institute, University of Maastricht, UNS50/23 Postbus 616, 6200 MD Maastricht, The Netherlands. Tel.: +31 43 388 2912; Fax: +31 43 388 4540; E-mail:
| |
Collapse
|
11
|
Abstract
There is overwhelming evidence that solid human tumours grow within a unique micro-environment. This environment is characterised by an abnormal vasculature, which leads to an insufficient supply of oxygen and nutrients to the tumour cells. These characteristics of the environment limit the effectiveness of both radiotherapy and chemotherapy. Measurement of the oxygenation status of human tumours has unequivocally demonstrated the importance of this parameter on patient prognosis. Tumour hypoxia has been shown to be an independent prognostic indicator of poor outcome in prostate, head and neck and cervical cancers. Recent laboratory and clinical data have shown that hypoxia is also associated with a more malignant phenotype, affecting genomic stability, apoptosis, angiogenesis and metastasis. Several years ago, scientists realised that the unique properties within the tumour micro-environment could provide the basis for tumour-specific therapies. Efforts that are underway to develop therapies that exploit the tumour micro-environment can be categorised into three groups. The first includes agents that exploit the environmental changes that occur within the micro-environment such as hypoxia and reduced pH. This includes bioreductive drugs that are specifically toxic to hypoxic cells, as well as hypoxia-specific gene delivery systems. The second category includes therapies designed to exploit the unique properties of the tumour vasculature and include both angiogenesis inhibitors and vascular targeting agents. The final category includes agents that exploit the molecular and cellular responses to hypoxia. For example, many genes are induced by hypoxia and promoter elements from these genes can be used for the selective expression of therapeutic proteins in hypoxic tumour cells. An overview of the various properties ascribed to tumour hypoxia and the current efforts underway to exploit hypoxia for improving cancer treatment will be discussed.
Collapse
Affiliation(s)
- B G Wouters
- Department of Experimental Radiation Oncology, UNS 50/ Box 23, azM/University of Maastricht, Postbox 616, 6200 MD Maastricht, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|